Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians

Abstract: Measurement-based care (MBC) can be defined as the clinical practice in which care providers collect patient data through validated outcome scales and use the results to guide their decision-making processes. Despite growing evidence supporting the effectiveness of MBC for depression and other mental health conditions, many physicians and mental health clinicians have yet to adopt MBC practice. In part, this is due to individual and organizational barriers to implementing MBC in busy clinical settings. In this paper, we briefly review the evidence for the efficacy of MBC focusing on pharmacological management of depression and provide example clinical scenarios to illustrate its potential clinical utility in psychiatric settings. We discuss the barriers and challenges for MBC adoption and then address these by suggesting simple solutions to implement MBC for depression care, including recommended outcome scales, monitoring tools, and technology solutions such as cloud-based MBC services and mobile health apps for mood tracking. The availability of MBC tools, ranging from paper-pencil questionnaires to mobile health technology, can allow psychiatrists and clinicians in all types of practice settings to easily incorporate MBC into their practices and improve outcomes for their patients with depression.

Keywords: measurement-based care, major depressive disorder, depression, scales, outcomes, patient-reported outcome measures, implementation, measurement

Introduction
Depression, or major depressive disorder (MDD), is a common mental health condition that affects people of all ages and is a leading cause of disease burden globally.1,2 Although there are many effective, evidence-based treatments for depression, as noted by clinical practice guidelines,3–6 remission rates are low with usual treatment indicating that these treatments produce suboptimal responses in clinical practice.7 Hence, there remains an unmet need to improve the usual care for depression treatment.

Standardizing the clinical management of patients with MDD is the first step to optimizing outcomes. The principles of clinical management include conducting a biopsychosocial assessment, formulating a differential diagnosis, supporting the patient through education, providing evidence-based treatments, and measuring clinical outcomes.8 Measuring clinical outcomes and using the results to guide treatment decisions is termed “measurement-based care” (MBC).9 However, unlike other areas of medicine where taking measurements is the norm (eg, blood pressure in patients with hypertension; fasting blood glucose and hemoglobin A1C in...
patients with diabetes), measuring outcomes is not routine in psychiatry. For mental health, outcome measurement can be accomplished using validated rating scales administered by clinicians or self-completed by patients. Routinely evaluating patients by using validated scales for symptoms, functioning and quality of life can help clinicians modify the course of treatment in a timely manner to better meet the needs of the patient. Hence, MBC can be applied to patients with any mental health diagnosis and treatment. The use of MBC has been shown to improve outcomes and quality of care in both psychiatric and primary care practice.\(^{10,11}\)

Despite the proven benefits of MBC, less than 20% of psychiatrists employ MBC in their practice, emphasizing the need to explore reasons for non-participation and to provide effective guidance for MBC implementation.\(^{12}\) With recent technological innovations in the field of medicine, new tools such as measurement feedback system technology and mobile apps for smartphones have been developed to improve the efficacy, applicability and implementation processes associated with MBC, as well as patient satisfaction.\(^{13}\) These tools can further empower patients by providing them with the ability to track their progress and become an active participant in their health care. Comprehensive reviews of MBC implementation are available,\(^{14}\) but in this paper, we briefly review the benefits and challenges of implementing MBC with a focus on pharmacological management of depression. We also provide some practical solutions and new technology tools for psychiatrists and primary care clinicians to incorporate MBC for depression into their clinical practice.

**Validated Outcome Scales**

The foundation for MBC is the use of validated outcome scales. Many scales have been developed to measure and understand the impact of chosen therapeutic intervention on the patient’s mental health.\(^{15}\) Rating scales for MBC have multiple uses, including screening, aiding in diagnosis, informing treatment adjustments and monitoring for relapse.\(^{16}\) Validated scales are available to assess clinically relevant outcomes such as symptoms, side effects, functioning, and quality of life. Symptom remission is an important outcome, but the goals of depression treatment should also encompass functional recovery and quality of life, which are higher priorities for patients.\(^{8,17}\) Although symptom and functional improvement are often associated, there is clear evidence that they are not highly correlated, nor do they improve along the same time course.\(^{18,19}\) Hence, it is important to assess each outcome independently using appropriate scales to ensure that treatment is optimized and that patients achieve symptom remission, functional recovery, and improved quality of life.

For outcome scales to be considered for MBC, they need to be psychometrically valid, reliable, sensitive to change, and relevant to specific setting and purpose.\(^{16}\) Care must be taken when evaluating the scales and scores by taking into consideration the context and individual differences of the patients, including their language, culture and cognitive state.\(^{16}\) Table 1 lists some examples of validated outcome scales for MBC of depression. The validated scales can be broadly classified into clinician-rated and patient-reported outcome measures (PROMs). Clinician-rated scales are thought to be more comprehensive but take additional training and are more time-consuming to administer,\(^{20}\) whereas PROMs take less time to complete but are more prone to subjective bias (such as depression-associated cognitive distortions). Regardless, there is usually a good correlation between scores on clinician-rated and patient-rated scales,\(^{21}\) so either type of scale can be used for MBC. Of course, like with laboratory tests, treatment decisions should not be made solely based on scores from outcome scales. Instead, the scores must be interpreted along with other data, within the patient’s individual context.

**Treatment Algorithms**

A treatment algorithm is a guideline that facilitates decision-making through a sequenced, stepwise approach for treatment recommendations.\(^{22}\) In conjunction with valid outcome scales, an empirically based algorithm for treatment decisions can be employed to deliver more systematic and optimized care.\(^{23}\) Many clinical guidelines provide algorithms for clinical decisions. For example, the Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guideline on pharmacological treatments for MDD\(^{24}\) provides first-line treatment options for MDD and strategies for managing patients who do not respond to the first medication.\(^{24}\) The Texas Medication Algorithm Project (TMAP) is another example of an algorithm that was designed to enhance the quality of pharmacotherapeutic intervention for depression by increasing the consistency of treatment among clinicians and promoting mutually agreed-upon decisions between patient and clinician.\(^{25}\) In a study exploring the effectiveness of TMAP, patients with MDD in clinics using the algorithm
displayed significantly better improvement in depressive symptom and quality of life outcomes compared to patients in matched clinics offering usual care.25

Although algorithms and guidelines may be evidence-based, the reality is that research evidence may not be directly applicable to the complexities of real-world clinical practice. Hence, clinicians are reminded that they must still take into account the unique patient context and tailor treatments to the individual patient.24

### Efficacy and Utility of MBC for Depression

Many reviews have highlighted the extensive empirical evidence that supports the utility of MBC in adult patients.10,11,26 However, the randomized controlled trial (RCT) evidence for efficacy is sparse, in part because of methodological heterogeneity in patient populations, settings, and outcome measures.27 A 2008 meta-analysis of 12 studies found a significant effect of outcome feedback to clinicians on short-term mental health outcomes, but the effect size (d=0.10; 95% confidence interval [CI], 0.01—0.19) was small.28 In contrast, a recent Cochrane systematic review was only able to include 12 RCTs using broad PROMs in adults with common mental disorders seen in multidisciplinary mental health or psychotherapy clinics.29 There was no difference in symptom outcomes between PROM feedback and no-feedback conditions but the quality of evidence was rated as low.29

Although MBC can be used for any treatment,10 it may be particularly useful for pharmacological management of adult depression where the efficacy of MBC is clearer. RCTs have shown that MBC, compared to usual care, improves both response and remission rates, as well as patient adherence to antidepressants. For example, Guo et al conducted a randomized, 24-week trial in a hospital outpatient clinic with 120 patients with MDD who were starting an antidepressant medication.87 The clinicians could choose to treat the patients in an open-label manner with either paroxetine or mirtazapine. The patients were randomized into either MBC or standard care; those in MBC completed the Quick Inventory of Depressive Symptomatology, Self-Rated (QIDS-SR)30 and Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)31 questionnaires at each visit, with scores given to their doctors to aid their decision-making for guidelines-concordant medication dose adjustment. Raters assessing patient outcomes were blinded to the randomized condition. Based on the primary Hamilton Depression Rating Scale32 outcomes over the course of 24 weeks, patients in the MBC condition achieved significantly higher response (87% vs. 63%, p=0.002) and remission (74% vs. 29%, p<0.001) rates in comparison to the patients in standard care. Rates of study discontinuation did not differ between the two conditions, suggesting that patients did not find completing the questionnaires at each visit to be an undue or intolerable burden.

| Table 1 Examples of Validated Outcome Scales for Measurement-Based Care of Depression |
|------------------------------------|------------------------------------|
| **Outcome** | **Clinician-Rated** | **Patient-Rated** |
| **Symptoms** | • Hamilton Depression Rating Scale (HAM-D)22 | • Patient Health Questionnaire (PHQ-9)13 |
| | • Montgomery-Asberg Depression Rating Scale (MADRS)74 | • Quick Inventory for Depressive Symptomatology, Self-Rated (QIDS-SR)30 |
| | • Inventory for Depressive Symptomatology (IDS)75 | • Clinically Useful Depression Outcome Scale (CUDOS)76 |
| | | • Patient-Reported Outcomes Measurement Information System (PROMIS) depression scale77 |
| **Functioning** | • Multidimensional Scale of Independent Functioning (MSIF)78 | • Lam Employment Absence and Productivity Scale (LEAPS)37 |
| | • WHO Disability Assessment Scale (WHO-DAS)58 | • Sheehan Disability Scale (SDS)59 |
| | • Social and Occupational Functioning Assessment Scale (SOFAS)79 | • WHO-DAS, self-rated60 |
| | | • Work Limitations Questionnaire (WLQ)81 |
| | | • Work Productivity and Activity Impairment (WPAI) scale82 |
| **Side Effects** | • UKU Side Effect Rating Scale83 | • Frequency, Intensity and Burden of Side Effects Rating (FIBSER)31 |
| **Quality of Life** | • Quality of Life Interview (QOLI)84 | • EuroQol-SD (EQ-5D-SL)60 |
| | | • PROMIS Global-1085 |
| | | • Quality of Life, Enjoyment and Satisfaction Questionnaire (QLESQ)86 |
Likewise, in a larger study involving over 900 patients, Yeung et al led a 6-month cluster-matched trial in primary care with the assignment of clinics to either MBC or standard care. Recruited patients were being treated for depression in primary care settings and were starting an antidepressant. In the MBC group, patients completed the Personal Health Questionnaire (PHQ-9) by telephone once a month and the scores were given to physicians who used them to guide their treatment decisions. After adjustment for demographic and clinical variables, the MBC group demonstrated twice the odds of attaining response (odds ratio [OR] 2.02, 95% CI 1.36–3.02) and 1.5 times the odds of attaining remission (OR 1.59, 95% CI 1.07–2.37) compared to the standard care group. Further, the study also explored the patients’ adherence to medications, in which they found that MBC group showed greater adherence (79% vs. 67%, p<0.01) compared to the standard care group.

The clinical utility of MBC for antidepressant treatment of depression can be illustrated in some simple scenarios described in Table 2. In these scenarios, compared to a clinician’s global assessment, the use of an outcome scale can identify at-risk situations and change the medication decision. Scenario 1 describes a situation where it may be difficult to detect early symptom change when a patient does not experience mood improvement. A depressive symptom scale such as the PHQ-9 or QIDS-SR can detect small changes in each symptom item that leads to a change in the total score. Typically, a change in the total score of ≥20% from baseline is usually greater than measurement error and day-to-day fluctuations in mood state, and thus is indicative of early clinical improvement. While a clinician may also detect small changes by inquiring about each symptom, these scales can save time and allow the clinician to focus on the most troubling symptoms. For the PHQ-9, a change of 5 points reflects a change of 2 standard deviations and is used to trigger a change in treatment.

In Scenario 2a, the patient has experienced a clinical response both globally and by the QIDS-SR score, typically defined as ≥50% improvement from baseline score. However, the patient has not yet attained the important goal of symptom remission, which is defined individually for each scale (eg, score of 0–4 for PHQ-9; 0–5 for QIDS-SR). In this case, MBC helped inform the decision to increase the medication dose. Again, using an outcome scale can more efficiently assess for symptom remission because clinicians do not need to inquire about every symptom. Scenario 2b shows the benefit of using a scale to assess medication side effects to optimize treatment adherence. The FIBSER is a simple 3-item assessment of frequency, intensity and burden of medication side effects; clinical decisions are based on the item that assesses the degree that side effects interfere with day-to-day activities. When side effect burden is rated as 0–2 (none, minimal or mild interference with activities), no action is needed, whereas ratings of 3–4 (moderate to marked interference) suggest that the side effect needs to be addressed (eg, by lowering the dose or using an antidote) and ratings of 5–6 (severe interference or being unable to function) usually requires changing treatment.

Scenario 2c illustrates how results from a functioning scale can alter treatment. The patient’s symptom scores are now in the remission range, with resulting improvement in social and family/home functioning. However, the Lam Employment Absence and Productivity Scale (LEAPS) score of 11 indicates that the patient is still having moderate work impairment, in part related to symptoms such as cognitive difficulties that only manifest while at work. Options include raising the dose or adding psychotherapy; in this case, moderate side effect burden and patient preference guide the treatment decision towards the addition of cognitive-behavioural therapy. Finally, Scenario 3 illustrates the benefit of using MBC during maintenance treatment to assess for signs of early relapse or recurrence. In this case, the patient completes the scales regularly at home and returns to the clinic for early intervention when scores are persistently above the remission threshold.

Although MBC is particularly useful for medication treatment and dose adjustments, MBC is also relevant and useful in psychotherapy. For example, mood monitoring and tracking is a foundational element of cognitive-behavioural therapy. Routine outcome monitoring may be particularly beneficial to identify patients who are not responding to treatment in order to consider early alternative action. MBC is also an important component of organized systems of primary mental health care, such as chronic disease management and collaborative care. For these reasons, both clinical guidelines and recent policy statements have called for the broad implementation of MBC for depression management.
<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Usual Care</th>
<th>Measurement-Based Care (Scores in Brackets)</th>
</tr>
</thead>
</table>
| Baseline  | • After assessment, the psychiatrist reviews the diagnosis of MDD with Jordan and prescribes an antidepressant medication. | • Jordan completes the scales and reviews them with the psychiatrist.  
• The QIDS-SR (16) indicates severe depressive symptoms and the SDS (26) indicates marked functional impairment.  
• The psychiatrist reviews the diagnosis of MDD with Jordan and prescribes an antidepressant medication.  
• Given the severity of the depression, they mutually decide to wait on psychotherapy until the symptoms have begun to improve.  
• The psychiatrist notes that the scales can help to monitor treatment progress. |
| Scenario 1 | • Given the lack of improvement, the psychiatrist decides to increase the dose of medication. | • The scales are completed and reviewed with Jordan.  
• The QIDS-SR (11) indicates moderately severe depressive symptoms; although the mood item is unchanged, there are slight improvements in the sleep, energy and concentration items.  
• The SDS score (22) still indicates marked functional impairment.  
• The psychiatrist explains that ≥20% reduction in QIDS-SR indicates a measurable improvement in symptoms and the SDS also shows some early functional improvement.  
• They discuss the discrepancy between lack of mood improvement and early improvement in other depressive symptoms.  
• Given this indication of early improvement, they mutually decide to keep the same dose of medication to see whether there will be a subsequent improvement in mood. |
| Scenario 2a | • Given the clear improvement, the psychiatrist decides to keep the same dose of medication. | • The scales are completed and reviewed with Jordan;  
• The QIDS-SR (8) indicates mild depressive symptoms. The FIBSER side effect burden score (2) indicates mild interference.  
• The psychiatrist explains that even though Jordan has a clinical response (≥50% reduction in QIDS-SR), there are still residual symptoms on sleep, energy and concentration items that might improve with a higher dose.  
• Given that Jordan’s side effect burden is tolerable, they mutually decide to increase the dose of medication. |

(Continued)
### Table 2 (Continued).

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Usual Care</th>
<th>Measurement-Based Care (Scores in Brackets)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scenario 2b</strong></td>
<td>At a follow-up visit at 8 weeks, Jordan reports, “I’m feeling better, but I’m having some pretty bad side effects from the medication.”</td>
<td>The psychiatrist decides to switch the antidepressant to another one.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The scales are completed and reviewed with Jordan.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The QIDS-SR (8) indicates mild depressive symptoms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The FIBSER indicates that although the side effects are markedly severe (4), they have low frequency (2) and low interference with activities (1).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Given a response on the QIDS-SR (&gt;50% improvement from baseline), the psychiatrist discusses ways to cope with the side effects.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>After discussion, they mutually decide to stay on the same antidepressant.</td>
</tr>
<tr>
<td><strong>Scenario 2c</strong></td>
<td>At a follow up visit at 8 weeks, Jordan reports, “I am feeling well and almost back to my usual self.”</td>
<td>The psychiatrist decides to maintain the dose of antidepressant.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The scales are completed and reviewed with Jordan.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The QIDS-SR (4) indicates minimal symptoms in the remission range.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The SDS (10) indicates moderate functional impairment with the LEAPS (11) showing moderate work impairment. The FIBSER (3) indicates a moderate burden of side effects.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In discussion, Jordan feels unable to tolerate an increase in dose and prefers a non-medication treatment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>They mutually decide to add CBT, which has been shown to improve work functioning in patients taking antidepressants.</td>
</tr>
<tr>
<td><strong>Scenario 3</strong></td>
<td>At a follow up visit at 16 weeks, Jordan reports, “I am now feeling and doing well, but what happens now?”</td>
<td>The psychiatrist notes that the antidepressant should be continued for another 6–8 months.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The scales are completed and reviewed with Jordan.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scores on the QIDS-SR, SDS, LEAPS and EQ-5D are all in the remission range.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The psychiatrist notes that the antidepressant should be continued for another 6–8 months.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jordan monitors mood changes by completing the scales at home every 2 months.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jordan returns to the clinic when the QIDS-SR (9) indicates mildly severe symptoms for more than 2 weeks, suggesting early relapse of symptoms.</td>
</tr>
</tbody>
</table>

**Abbreviations:** MDD, major depressive disorder; QIDS-SR, Quick Inventory of Depressive Symptomatology, Self-Rated; SDS, Sheehan Disability Scale; FIBSER, Frequency, Intensity, Burden of Side Effects Rating; LEAPS, Lam Employment Absence and Productivity Scale; CBT, cognitive-behavioural therapy; EQ-5D, EuroQol-5D.

### Barriers and Facilitators to MBC Implementation

Despite the evidence and recommendations for MBC, there is still a significant care gap in the implementation and routine use of MBC. Aside from a few health care systems where routine outcome monitoring is an established practice (e.g., in the United Kingdom and the Netherlands), only a minority of physicians and mental health professionals incorporate MBC into routine practice.
health clinicians use MBC for depression. Barriers to using MBC can occur at multiple levels including at clinician, organization/system, and patient levels. In a survey of 314 psychiatrists, 61% indicated that they never or rarely used standardized scales; only 18% used them frequently or all the time. However, of the reasons given by psychiatrists for not using a scale, only 28% responded that they did not believe it would be clinically helpful. Other reasons included not knowing which scales to use (21%), taking too much time (34%), being too disruptive of clinical practice (19%) and not being trained to use them (34%).

There are also organizational and system barriers to MBC implementation in clinical practice settings. Without financial incentives, clinics may find it challenging to incorporate MBC into busy workflow. Training clinicians about MBC may take additional resources. Charting and monitoring changes in scales in clinical records may be difficult; those with electronic medical records (EMRs) may need to adapt them to incorporate mental health measurements. There may also be barriers for patients to complete questionnaires, for example, if they do not understand the purpose of the measures or if they are long and burdensome to complete.

Despite these challenges and barriers, there are encouraging facilitators to implement MBC in clinical practice. Patients report that they enjoy completing the questionnaires and want their clinicians to use the results in their care. MBC training can be incorporated into psychiatry and family practice residency curricula and continuing professional development. Comprehensive guides are available for organizations to implement MBC in diverse clinical settings.

In the following sections, we provide some simple solutions and practical recommendations, including the use of new technology tools, as guidance for clinics and individual physicians to incorporate MBC for depression into their practice.

Practical Use of Scales for MBC of Depression

Although some research suggests the use of individualized outcome measures may be more acceptable to clinicians, most guidelines for MBC recommend using standardized outcome scales. We provide an exemplary set of validated, standardized scales for adult patients with depression that we use in our clinic (Table 3). These scales assess important outcomes and address many of the perceived and actual barriers for implementing MBC. The recommended scales are simple, brief, free or low-cost, and available in several languages. We chose PROMs because of efficiency and ease-of-use; the 6 scales take only 10–15 minutes for patients to complete.

For symptoms, we recommend using either the PHQ-9 or the QIDS-SR. Both are based on the nine symptom criteria for MDD in the DSM-5 and thus can be used as a diagnostic aid as well as assessing severity and change over time. The difference between the two is that the PHQ-9 includes only single items to assess sleep, appetite/weight, and psychomotor activity, whereas the QIDS-SR includes separate items to assess the type of insomnia and both psychomotor retardation and agitation, as well as atypical features such as hypersomnia, overeating, and weight gain. Scoring for the QIDS-SR, however, is based only on the nine DSM-5 symptom criteria, so the total scores of the QIDS-SR and PHQ-9 are similar. Of note, the

Table 3 An Example of Recommended Patient-Rated Scales for Measurement-Based Care for Depression

<table>
<thead>
<tr>
<th>Outcome Type</th>
<th>Scale</th>
<th>Number of Items</th>
<th>Time to Complete (Minutes)*</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>PHQ-9 or QIDS-SR; GAD-7</td>
<td>9</td>
<td>3–5</td>
<td>Free</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>5–7</td>
<td>Free</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>3</td>
<td>Free</td>
</tr>
<tr>
<td>Functioning</td>
<td>SDS; LEAPS</td>
<td>3</td>
<td>3</td>
<td>May require fee</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
<td>3–5</td>
<td>Free for clinical use</td>
</tr>
<tr>
<td>Quality of Life</td>
<td>EQ-5D</td>
<td>5</td>
<td>3</td>
<td>Free for non-commercial organizations</td>
</tr>
<tr>
<td>Side Effects</td>
<td>FIBSER</td>
<td>3</td>
<td>3</td>
<td>Free</td>
</tr>
</tbody>
</table>

Notes: *Note, these times indicate the time required per individual scale on first-time assessment; however, less time is usually required when several scales are done at once, and when scales are done on repeat assessment.

Abbreviations: PHQ-9, Patient Health Questionnaire; QIDS-SR, Quick Inventory for Depressive Symptomatology, Self-Rated; GAD-7, Generalized Anxiety Disorder scale; SDS, Sheehan Disability Scale; LEAPS, Lam Employment Absence and Productivity Scale; EQ-5D, EuroQol-5D; FIBSER, Frequency, Intensity, Burden of Side Effects Rating.
PHQ-9 is the only brief symptom scale that includes an assessment of the presence and degree of functional impairment (question 10). Hence, the QIDS-SR is a more comprehensive symptom assessment tool than the PHQ-9, but it requires a separate assessment of impairment. We include the Generalized Anxiety Disorder scale (GAD-7) as a measure of anxiety because it is so commonly experienced with depression and has implications for treatment. Although some international groups have recommended the World Health Organization Disability Assessment Schedule (WHO-DAS), we chose the Sheehan Disability Scale (SDS) as a global measure of functional impairment because it is widely used in depression studies, particularly in antidepressant clinical trials, and is shorter and quicker to complete. The LEAPS is included as a more specific measure of work impairment developed for use in patients who continue to work while being treated for depression. Finally, we use the EuroQol 5D (EQ-5D-5L) as a brief measure of the quality of life.

Patients can complete the questionnaires in the waiting room before their appointment and score the questionnaires themselves before seeing the psychiatrist, whereupon the scores are reviewed together. The scales are completed at baseline assessment and, because the questions cover the past 1 or 2 weeks, at each subsequent visit which usually occurs every 2–3 weeks during acute treatment. Once patients have remitted, the scales only need to be done every month or two to monitor for relapse. We also have a summary form for the patient record in which the scores for each visit can be easily entered, visually tracked and monitored during treatment; eg, remission criteria are clearly marked as a goal for treatment. All these scales and forms can be downloaded at our website, https://bit.ly/2ZXj6gd.

Technology Tools for MBC

Of course, many clinicians now have access to EMRs which vary in utility and complexity. Many commercially available EMRs have incorporated measurement for mental health outcomes with dashboards that allow tracking of scores over time with visual graphing of results. An additional value of MBC facilitated by these platforms is the efficient communication about patients by the care team, including between primary care and psychiatrists. Some EMRs also have the capability to send online PROMs to patients via email, with direct importing of results into the EMR. Academic organizations have also developed simple MBC platforms for electronic data capture of patient-reported outcomes. More complex (and expensive) health technology incorporating a measurement-feedback system linked to guideline recommendations and decision support is also available and effective for MBC. For individuals and organizations that do not have access to EMRs or have difficulty modifying their existing EMR, web-based MBC services may provide a solution. Owl Insights (www.owlinsights.com) is an example of a commercial service that integrates MBC through a cloud-based platform that includes screening patients for mental health conditions, tracking their progress with PROMs, and providing guidance for evidence-based treatment. With the process largely automated and digitalized, patients can complete questionnaires on their own time and have their data analyzed and sent electronically to the provider for review.

VitalSigns is another example of a point-of-care, web-based software program that can be integrated into EMRs to enable MBC for screening and treatment of depression in primary care settings.

Finally, the emergence of online and mobile apps as potential health technology tools, particularly highlighted during the global COVID-19 pandemic crisis, has made digital mental health increasingly important for mental health care. The process of putting mood and outcome tracking directly into the hands of patients enables them to become active participants in shared decision-making with their health care providers. For example, we have created MoodFx (pronounced mood effects, www.moodfx.ca), an online mood tracking application optimized for mobile devices. MoodFx is a free, simple, and patient-focused MBC tool that incorporates validated outcome scales (eg, PHQ-9, GAD-7, FIBSER, LEAPS, SDS) with visual results through graphs and charts that patients can print out or show on their mobile device to physicians or other mental health clinicians. Within MoodFx, users can also schedule reminders via text or email to regularly complete questionnaires and subscribe to receive weekly tips on depression self-management (see https://bit.ly/3mG2qTU). Another screening and monitoring app is What’s My M3 (https://whatsmym3.com), which can track mood and screen for multiple mental disorders including MDD, bipolar disorder and post-traumatic stress disorder. Depression Monitor is another simple, validated mobile app that uses the PHQ-9 to screen for depression and to illustrate the patient’s depressive symptoms to their clinicians.

While these and other digital tools can empower patients, allow clinicians to use scales without major changes to their practice, and support shared decision-making within an MBC framework, there are barriers and limitations to using apps for mental health care.
Online and mobile depression applications still show little uptake by patients, although attention to specific components such as self-tracking, goal setting and educational learning may increase engagement. Very few mental health apps have been adequately evaluated for effectiveness or harms, although recent efforts are converging on consensus evaluation frameworks. Security and privacy concerns are paramount among patients, hence apps should have transparent policies for how data are used, shared and protected. Some patients may have limited access to technology because of financial, language, wireless availability, or digital literacy challenges. Finally, depression-associated cognitive dysfunction may interfere with the patient’s use of digital technologies at home.

Conclusion

There is ample evidence that MBC is effective in improving treatment outcomes for patients with MDD. MBC benefits patients (to understand and track their symptoms), clinicians (to guide treatment decisions), and organizations (to standardize care and for quality improvement). Even though many clinicians and organizations want to adopt MBC, there are still multiple barriers and challenges for MBC implementation. However, PROMs and new technological tools may address many of the perceived barriers to the use of MBC and allow patients to track their own outcomes and become active participants in shared decision-making. For clinicians and practice settings where technology is not an option, simple methods including the use of “paper-pencil” patient-rated scales and monitoring forms can increase efficiency and streamline workflow for MBC implementation. These recommended solutions can help clinicians to successfully overcome the challenges of adopting MBC and to ensure that patients have access to best practices for depression management and outcomes.

Acknowledgment

Co-senior authors: Raymond W Lam and Jun Chen.

Funding

This manuscript was supported by the Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) study, funded by the Canadian Institutes of Health Research (CIHR) and the National Natural Sciences Foundation of China (81761128032) through the Global Alliance on Chronic Disease [CIHR Team Grant: GACD Mental Health, GAC-154985; Agreement #01709-000]. RHH was supported by a Mach-Gaensslen Foundation of Canada Award through the UBC Faculty of Medicine Summer Student Research Program.

Disclosure

Ran Ha Hong reports grants from UBC Faculty of Medicine, during the conduct of the study. Jill K Murphy reports grants from Global Alliance for Chronic Disease/Canadian Institutes of Health Research, during the conduct of the study. Erin E. Michalak has received funding to support patient education initiatives from Otsuka. Trisha Chakrabarty reports grants from Michael Smith Foundation for Health Research and National Research Council Canada, outside the submitted work. Sagar V. Parikh reports grants and personal fees from Takeda, grants from Sage, personal fees from Afred, Mensante, and Janssen, outside the submitted work. Larry Culpepper reports personal fees from AbbVie Pharmaceuticals, Allergan Pharmaceuticals, Acadia Pharmaceuticals, Eisai, Merck, Takeda and Physicians Postgraduate Press, owns stock in M3 Information, outside the submitted work. Lakshmi N. Yatham reports personal fees from Alkermes, DSP, Merck, Intracellular Therapeutics, Sanofi, Lundbeck, and Sunovion, grants from Allergan, outside the submitted work. Raymond W. Lam reports grants from Canadian Institutes of Health Research, during the conduct of the study; personal fees from Allergan, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Hansoh, Janssen, Lundbeck, Lundbeck Institute, Myriad Neuroscience, Otsuka, and Pfizer, and grants from Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Healthy Minds Canada, Michael Smith Foundation for Health Research, MITACS, Ontario Brain Institute, St. Jude Medical, University Health Network Foundation, and VGH-UBCH Foundation, outside the submitted work. The authors report no other potential conflicts of interest for this work.

References


